WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced the appointment of Jay Dixon as senior vice president, global quality and compliance. Dixon’s expertise will enhance PPD’s ability to deliver industry-leading drug development services and high-quality data across the full spectrum of the research and development life cycle.
“In today’s changing regulatory landscape, quality and compliance programs must continually evolve to meet and exceed international guidelines,” said David Simmons, PPD chairman and chief executive officer. “Jay’s combination of leadership skills and biopharmaceutical and contract research organization experience will enable PPD to continue fulfilling its commitment to providing superior quality and compliance solutions for clients.”
PPD conducts quality assurance and compliance programs for laboratory services and clinical development services throughout the world by promoting a unified, risk-based approach. These comprehensive programs, combined with thorough assessment and insightful recommendations, helps clients and sites develop the most effective action plans. PPD provides a proactive, data-driven quality and compliance program that detects signals and trends, while profiling and integrating risk management to assure processes, systems and projects are inspection-ready and compliant at all times.
“Biopharmaceutical companies depend on PPD’s quality and compliance programs to help protect the integrity of their research and development programs,” Dixon said. “By ensuring adherence to protocols and international regulatory guidelines, we are helping our clients bring needed therapies to market while protecting the welfare and rights of clinical trial participants.”
Dixon is a seasoned executive with more than 27 years of research and development experience in the pharmaceutical and biotechnology industries. Most recently, he was chief operating officer at PRACS Institute, with responsibility for providing strategic direction and leadership to the company’s service lines, quality infrastructure, management and business development activities. Previously, he served as senior vice president of regulatory affairs, quality and compliance, as well as chief compliance officer. In addition, Dixon has served in quality and compliance roles with MedImmune, Abbott Laboratories, GlaxoSmithKline and two contract research organizations.
Dixon is a member of the Drug Information Association and the Society of Quality Assurance. He formerly was a member of the board of directors of Frederick Memorial Healthcare System, where he served on the quality committee and chaired the audit and compliance committee. He holds a bachelor’s degree in biology from Campbell University.
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s global quality and compliance appointment, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate and retain key personnel, including our new senior vice president, global quality and compliance; competition in the outsourcing industry; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD’s ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to control SG&A spending; and rapid technological advances that make our services less competitive. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.